// Workers AI · dad joke modeWhat did XL-388 say to its date? You're extra large to me.

XL-388
Identifiers
	IUPAC name [7-(6-aminopyridin-3-yl)-3,5-dihydro-2H-1,4-benzoxazepin-4-yl]-(3-fluoro-2-methyl-4-methylsulfonylphenyl)methanone;
CAS Number	1251156-08-7 ;
PubChem CID	59604787;
ChemSpider	28824127;
UNII	B7I5G3Z7XR;
ChEMBL	ChEMBL2333365;
CompTox Dashboard (EPA)	DTXSID901336669 ;
Chemical and physical data
Formula	C23H22FN3O4S
Molar mass	455.50 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C=CC(=C1F)S(=O)(=O)C)C(=O)N2CCOC3=C(C2)C=C(C=C3)C4=CN=C(C=C4)N;
	InChI InChI=1S/C23H22FN3O4S/c1-14-18(5-7-20(22(14)24)32(2,29)30)23(28)27-9-10-31-19-6-3-15(11-17(19)13-27)16-4-8-21(25)26-12-16/h3-8,11-12H,9-10,13H2,1-2H3,(H2,25,26); Key:LNFBAYSBVQBKFR-UHFFFAOYSA-N;

XL-388 is a drug which acts as a potent and selective inhibitor of both subtypes of the mechanistic target of rapamycin (mTOR), mTORC1 and mTORC2.^[1] It is being researched for the treatment of various forms of cancer,^[2]^[3]^[4] and has also been used to demonstrate a potential application for mTOR inhibitors in the treatment of neuropathic pain.^[5]^[6]

References

↑ Takeuchi CS, Kim BG, Blazey CM, Ma S, Johnson HW, Anand NK, et al. (March 2013). "Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR)". Journal of Medicinal Chemistry. 56 (6): 2218–34. doi:10.1021/jm3007933. PMID 23394126.
↑ Zhu YR, Zhou XZ, Zhu LQ, Yao C, Fang JF, Zhou F, et al. (August 2016). "The anti-cancer activity of the mTORC1/2 dual inhibitor XL388 in preclinical osteosarcoma models". Oncotarget. 7 (31): 49527–49538. doi:10.18632/oncotarget.10389. PMC 5226526. PMID 27385099.
↑ Xiong Z, Zang Y, Zhong S, Zou L, Wu Y, Liu S, et al. (May 2017). "The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent". Oncotarget. 8 (18): 30151–30161. doi:10.18632/oncotarget.15620. PMC 5444733. PMID 28404914.
↑ Zhong S, Xue J, Cao JJ, Sun B, Sun QF, Bian LG, et al. (November 2020). "The therapeutic value of XL388 in human glioma cells". Aging. 12 (22): 22550–22563. doi:10.18632/aging.103791. PMC 7746352. PMID 33159013.
↑ Choi S, Kim K, Cha M, Kim M, Lee BH (January 2020). "mTOR signaling intervention by Torin1 and XL388 in the insular cortex alleviates neuropathic pain". Neuroscience Letters. 718 134742. doi:10.1016/j.neulet.2020.134742. PMID 31917234.
↑ Cha M, Choi S, Kim K, Lee BH (November 2020). "Manganese-enhanced MRI depicts a reduction in brain responses to nociception upon mTOR inhibition in chronic pain rats". Molecular Brain. 13 (1) 158. doi:10.1186/s13041-020-00687-1. PMC 7713325. PMID 33267907.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by adding missing information.

This analgesic-related article is a stub. You can help Wikipedia by adding missing information.

[1] Takeuchi CS, Kim BG, Blazey CM, Ma S, Johnson HW, Anand NK, et al. (March 2013). "Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR)". Journal of Medicinal Chemistry. 56 (6): 2218–34. doi:10.1021/jm3007933. PMID 23394126.

[2] Zhu YR, Zhou XZ, Zhu LQ, Yao C, Fang JF, Zhou F, et al. (August 2016). "The anti-cancer activity of the mTORC1/2 dual inhibitor XL388 in preclinical osteosarcoma models". Oncotarget. 7 (31): 49527–49538. doi:10.18632/oncotarget.10389. PMC 5226526. PMID 27385099.

[3] Xiong Z, Zang Y, Zhong S, Zou L, Wu Y, Liu S, et al. (May 2017). "The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent". Oncotarget. 8 (18): 30151–30161. doi:10.18632/oncotarget.15620. PMC 5444733. PMID 28404914.

[4] Zhong S, Xue J, Cao JJ, Sun B, Sun QF, Bian LG, et al. (November 2020). "The therapeutic value of XL388 in human glioma cells". Aging. 12 (22): 22550–22563. doi:10.18632/aging.103791. PMC 7746352. PMID 33159013.

[5] Choi S, Kim K, Cha M, Kim M, Lee BH (January 2020). "mTOR signaling intervention by Torin1 and XL388 in the insular cortex alleviates neuropathic pain". Neuroscience Letters. 718 134742. doi:10.1016/j.neulet.2020.134742. PMID 31917234.

[6] Cha M, Choi S, Kim K, Lee BH (November 2020). "Manganese-enhanced MRI depicts a reduction in brain responses to nociception upon mTOR inhibition in chronic pain rats". Molecular Brain. 13 (1) 158. doi:10.1186/s13041-020-00687-1. PMC 7713325. PMID 33267907.

[1]

[2]

[3]

[4]

[5]

[6]

This page was redesigned at the edge.

A page that knows where it met you.

// Workers AI · dad joke modeWhat did XL-388 say to its date? You're extra large to me.

References